To ask the Secretary of State for Health and Social Care, what his planned timetable is for making a decision on the use of Evusheld following conclusion of UKHSA testing.

AstraZeneca commissioned the UK Health Strategic Authority to conduct studies into the effectiveness of Evusheld against the Omicron variants. Initial data has been shared with AstraZeneca. The Department is also assessing Evusheld through requesting advice from clinicians on the most appropriate option for the National Health Service in line with available data, the public health situation and other treatments available. While we expect to receive clinical advice shortly we are unable to confirm a specific timetable.